$TMV #AIinPharma--Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thoug...
Autore: Business Wire
Board unites senior regulatory, quality, investment, and AI leaders from Boehringer Ingelheim, Takeda, Gilead Sciences, Serrado Capital, and Stanford University
SAN FRANCISCO: $TMV #AIinPharma--Weave Bio, the leader in AI-native regulatory automation, today announced the formation of its inaugural Strategic Advisory Board (SAB). Bringing together senior executives and thought leaders with expertise spanning pharma regulatory strategy and operations, health authority policy and practice, capital markets, and academic research, the SAB will serve as a strategic forum to guide the evolution of the Weave Platform and advance the responsible adoption of AI across the life sciences regulatory ecosystem.
"Regulatory workflows are the backbone of a therapeutic candidate's success, and for too long they have been defined by manual, time-consuming processes that slow the path from discovery to patients," said Brandon Rice, Co-Founder and CEO of Weave Bio. "Our Strategic Advisory Board brings together experts who are actively shaping how the industry operates today and where it must go tomorrow. Their guidance will ensure our team is building technology that is not only powerful, but deeply trusted by the organizations we serve."
The Weave Bio Strategic Advisory Board includes the following inaugural members, who will bring firsthand experience navigating the regulatory systems, health authority interactions, and scientific standards that define the field:
"We are at a defining moment for regulatory science. AI has the potential to make the regulatory process more intelligent, more efficient, and ultimately more predictable, but only if it is built on a foundation of deep regulatory understanding. I believe that Weave Bio is approaching this transformation in the right way, starting with the end goal and letting the science and technology follow,” said Chris Lee, Vice President, Regulatory Affairs Innovation and Strategic Operations, Gilead.
"The regulatory domain demands a higher bar than most. The consequences of errors are measured in patient outcomes, not just operational inefficiencies. Weave Bio understands this, and their approach to human-AI collaboration in regulatory workflows reflects the kind of principled engineering our field needs," said Russ Altman, Kenneth Fong Professor and Senior Fellow at the Stanford Institute for Human-Centered AI, Stanford University.
The formation of the SAB builds on a period of significant momentum for Weave Bio. In October 2025, the company secured a $20 million Series A funding round to accelerate the expansion of its AI-native platform across the full regulatory lifecycle, from IND through NDA, BLA, and post-market submissions. That same month, Weave Bio announced a strategic partnership with Parexel to drive innovation in early regulatory authoring and submission processes. The SAB marks the next step in this trajectory, ensuring the company’s technology remains deeply aligned with the operational, scientific, and policy realities of modern drug development.
About Weave Bio
Weave Bio is an AI-native software company transforming how novel therapies navigate the complex path from lab to market. The Weave Platform streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants by infusing AI into every step of the workflow-from data extraction and authoring to review and verification, yielding compliant, submission-ready regulatory dossiers with unprecedented speed.
The Weave Platform has been widely adopted for preclinical IND preparation and has earned industry recognition as the "Biotech AI Innovation of the Year" award winner. Weave has since expanded to support clinical-stage submissions, delivering a comprehensive AI workbench that accelerates regulatory timelines by more than 50% while improving review quality and ensuring compliance with FDA, EMA, and global regulatory standards.
Founded in 2022 and headquartered in San Francisco, Weave Bio bridges regulatory expertise, AI innovation, and enterprise software to solve critical bottlenecks in drug development. Backed by leading investors including USVP, Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital, and trusted by innovative biopharma companies worldwide, Weave is building the new standard in regulatory automation.
For more information, visit weave.bio and follow us on LinkedIn.
Fonte: Business Wire